

Sent by email to: [REDACTED]

[REDACTED]
[REDACTED],

Pfizer Limited,
Walton Oaks, Dorking Road,
Walton on the Hill,
Tadworth,
Surrey
KT20 7NS

14 December 2020

Dear [REDACTED] [REDACTED]

**Re: APPEAL AGAINST THE FINAL APPRAISAL DETERMINATION FOR
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH
CARDIOMYOPATHY**

Thank you for your letter of 10 December 2020. I apologise for having inadvertently omitted point 2.8 from the list of valid appeal points.

I agree that time for any judicial review would not begin to run until you have been told the outcome of the appeal, and that this would apply equally to the appeal points not permitted to proceed to hearing as it does to the points which the appeal panel will consider.

Many thanks

Yours sincerely

Tim Irish
Vice Chair
National Institute for Health and Care Excellence